255 related articles for article (PubMed ID: 9854445)
1. MedWatch. FDA's 'heads up' on medical product safety.
Henkel J
FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
[No Abstract] [Full Text] [Related]
2. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
3. MedWatch: the FDA medical products reporting program.
Rheinstein PH
Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
[No Abstract] [Full Text] [Related]
4. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
5. Medical device safety: FDA's postmarket transformation initiative.
Schultz D
Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401
[No Abstract] [Full Text] [Related]
6. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
7. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
8. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
9. The Safe Medical Devices Act of 1990--FDA. Notice.
Fed Regist; 1991 Apr; 56(66):14111-3. PubMed ID: 10111151
[TBL] [Abstract][Full Text] [Related]
10. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
11. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
12. MEDWatch: medical products reporting program.
Minarik PA
Clin Nurse Spec; 1994 Mar; 8(2):74, 68. PubMed ID: 7882246
[No Abstract] [Full Text] [Related]
13. Reporting of adverse drug events: a key to postmarketing drug safety.
Rheinstein PH
Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
[No Abstract] [Full Text] [Related]
14. MedWatch: FDA's Medical Products Reporting Program.
Goldman SA; Kennedy DL
Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
[No Abstract] [Full Text] [Related]
15. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
Browar S
Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
[TBL] [Abstract][Full Text] [Related]
16. Science and regulation. FDA's approach to regulation of products of nanotechnology.
Hamburg MA
Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
[No Abstract] [Full Text] [Related]
17. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
18. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
19. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
20. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
